It is a fictional representation created for illustrative purposes only. AstraZeneca's experimental precision drug, developed ...

It said the drug did not 'achieve statistical significance' in terms of the survival rates of those suffering from breast ...

Intel jumps on reports of Apollo investment and Qualcomm takeover interest, Palantir and Dell join the S&P 500, and TSMC and Samsung reportedly mulling UAE chip megafactories. Here's what investors ...

AstraZeneca Plc (NASDAQ:AZN) released high-level results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival ...

European stock markets were up at midday as investors digested eurozone survey results, while Commerzbank shares were in focus after the German government decided to keep its stake in the lender.

patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial Survival results for AstraZeneca and Daiichi Sankyo's datopotamab deruxtecan in ...

AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate failed a key survival endpoint in a late-phase breast ...

AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab ...

The experimental drug Astrazeneca used against breast cancer has proven not to work as hoped. The stock, listed in London, is ...

(Reuters) -European shares edged higher on Monday, though gains were capped by caution as investors tread carefully in ...

(Alliance News) - AstraZeneca PLC on Monday said a breast cancer drug failed to significantly extend patients' lives, a second blow this month to hopes for the product. Datopotamab deruxtecan, also ...